Masimo (MASI)
(Delayed Data from NSDQ)
$115.05 USD
+1.03 (0.90%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $115.15 +0.10 (0.09%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$115.05 USD
+1.03 (0.90%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $115.15 +0.10 (0.09%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
McKesson Banks on Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson (MCK) entered fiscal 2018 with an assumption of branded inflation in the mid-single digits. Pricing pressure in the independent retail pharmacy channel is a headwind.
BioTelemetry Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
BioTelemetry (BEAT) is putting efforts in product innovation through research and development. The company recently announced the acquisition of LifeWatch AG in a deal valued at about $280 million.
Masimo (MASI) Introduces SafetyNet System in Dubai Hospitals
by Zacks Equity Research
Masimo's (MASI) proprietary Patient SafetyNet system's introduction in the Dubai market is in line with its strategy of becoming the dominant player in the pulse oximetry market.
Zacks.com featured highlights: CBRE Group, Canadian Pacific Railway, East West Bancorp, Hasbro and Masimo
by Zacks Equity Research
Zacks.com featured highlights: CBRE Group, Canadian Pacific Railway, East West Bancorp, Hasbro and Masimo
Top 5 GARP Stocks to Scoop Up Right Now
by Zacks Equity Research
The GARP approach prefers stocks that are priced below the market or any reasonable target determined by fundamental analysis.
Masimo (MASI) Beats on Q2 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo's (MASI) stable performance across its businesses was the key highlight of second quarter.
MedTech Stock Earnings Slated for Aug 2: CAH, HOLX & More
by Zacks Equity Research
Despite solid strategic initiatives, the ongoing political conundrum at the Capitol Hill is likely to affect earnings results of these four major Medical Technology bigwigs.
Masimo (MASI) Rainbow Super DCI-mini Sensor Now CE Marked
by Zacks Equity Research
Irvine, CA-based Masimo Corporation (MASI) recently announced the receipt of CE mark for the noninvasive and reusable rainbow Super DCI-mini sensor.
Masimo (MASI) Presents Utility Study of Oxygen Reserve Index
by Zacks Equity Research
Masimo Corporation (MASI) recently announced data from its study evaluating the potential clinical utility of Masimo Oxygen Reserve Index.
Zacks.com featured highlights: 58.com, RPC, U.S. Silica Holdings, Masimo and Manitowoc
by Zacks Equity Research
Zacks.com featured highlights: 58.com, RPC, U.S. Silica Holdings, Masimo and Manitowoc
5 Stocks to Watch for Accelerating Earnings Growth
by Tirthankar Chakraborty
Earnings acceleration should be viewed as a key metric for share price outperformance
Masimo (MASI) O3 Regional Oximetry Device Gets FDA Nod
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of FDA 510(k) clearance for O3 regional oximetry device.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Zacks.com featured highlights: Ituran Location and Control, Molina Healthcare, WellCare Health Plans and Masimo
by Zacks Equity Research
Zacks.com featured highlights: Ituran Location and Control, Molina Healthcare, WellCare Health Plans and Masimo
4 Top-Ranked Liquid Stocks for a Winning Portfolio
by Zacks Equity Research
Liquidity of a stock primarily indicates a company's capability to meet debt obligations by converting assets into liquid cash and equivalents.
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.
Masimo (MASI) Launches Root Platform with Kite Trademark
by Zacks Equity Research
Irvine, CA-based Masimo Corporation (MASI) announced full market release of the Root monitoring platform with a Kite trademark (a supplementary display system).
Obamacare Holds Ground: 3 Medical Device Stocks to Gain
by Zacks Equity Research
Republican leaders have failed to play their "Trump card" this time, courtesy of the pullback of the Republican healthcare bill, the American Health Care Act (ACHA), which was designed to repeal the Affordable Care Act (ACA) or Obamacare.
Masimo (MASI) Up 20.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Medical Device Stocks to Brave Policy Uncertainty
by Zacks Equity Research
We believe stocks with strong fundamentals that also have a significant share of their business overseas may well brace themselves in the on-going conundrum. They will make lucrative additions to your portfolio.
Can The Uptrend Continue for Masimo (MASI)?
by Zacks Equity Research
Investors certainly have to be happy with Masimo Corporation (MASI) and its short term performance
Masimo Announces Availability of RD SedLine Brain Sensors
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the availability of the RD SedLine EEG sensor, which can be used with the company???s flagship SedLine Brain Function Monitoring technology.